olorinab

Ligand id: 10058

Name: olorinab

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 106.46
Molecular weight 357.18
XLogP 1.19
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
International Nonproprietary Names
INN number INN
10809 olorinab
Synonyms
APD-371 | APD371 | compound 6 [PMID: 29259753]
Comments
Olorinab (APD371) is a cannabinoid CB2 receptor agonist that is being developed by Arena Pharmaceuticals as a potential treatment for chronic pain [1]. In vitro, APD371 is as efficacious as the CB2 receptor full agonist CP55940 (as determined by measuring and comparing Emax values), and has limited tachyphylaxis liability (i.e. it does cause agonist-induced desensitization due to impeding the return of internalized agonist-activated receptors back to the plasma membrane) .
Database Links
CAS Registry No. 1268881-20-4 (source: WHO INN record)
GtoPdb PubChem SID 375973246
PubChem CID 60164925
Search Google for chemical match using the InChIKey ACSQLTBPYZSGBA-GMXVVIOVSA-N
Search Google for chemicals with the same backbone ACSQLTBPYZSGBA
Search PubMed clinical trials olorinab
Search PubMed titles olorinab
Search PubMed titles/abstracts olorinab
Search UniChem for chemical match using the InChIKey ACSQLTBPYZSGBA-GMXVVIOVSA-N
Search UniChem for chemicals with the same backbone ACSQLTBPYZSGBA